Abstract
Osteosarcoma, or osteogenic sarcoma, is a primary malignant bone tumor with a variety of histological subtypes grouped into three categories, each one with a different prognosis. As a malignant tumor, it has the capacity of making early metastasis, being the lung being the most frequent secondary location. The most common location is in either in the lower extremity around the knee or in the upper extremity in the proximal humerus. The diagnosis is made considering clinical aspects, radiology and histology. The therapy has evolved in the past decade and it includes a combination of radical surgery, chemotherapy and immunotherapy. The decision is made according to the histological subtype, size and the presence of metastasis. The main prognostic factors are location, histological type, size of the tumor and metastasis at the moment of diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Misaghi A.Osteosarcoma: a comprehensive review. SICOT J 2018; 4:12. https://doi.org/10.1051/sicotj/2017028. Epub April 9, 2018.
Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43(6):2163–77.
Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the cooperative osteosarcoma study group. J Clin Oncol. 2003;21(2):334–41.
Malek F, Somerson JS, Mitchel S, Williams RP. Does limb-salvage surgery offer patients better quality of life and functional capacity than amputation? Clin Orthop Relat Res. 2012;470(7):2000–6.
Nystrom LM, Morcuende JA. Expanding endoprosthesis for pediatric musculoskeletal malignancy: Current concepts and results. Iowa Orthop J. 2010; 30:141–149.
DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61(2):492–8.
Brosjö O. Surgical procedure and local recurrence in 223 patients treated 1982–1997 according to two osteosarcoma chemotherapy protocols: The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl. 1999;285:58–61.
Moore DD et al. Advances in targeted therapy for osteosarcoma. Zhou W. et al. Discov Med Cancer Treat Res. 2014;162: 65–92. https://doi.org/10.1007/978-3-319-07323 PMID: 25070231, https://doi.org/10.1007/978-3-319-07323-1_4.
Hawkins DS, Conrad EU III, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115(15):3519–25.
Wang D, Tang L, Wu H, Wang K, Gu D. MiR-127–3p inhibits cell growth and invasiveness by targeting ITGA6 in humanosteosarcoma. IUBMB Life. 2018; 70(5):411–419. https://doi.org/10.1002/iub.1710. Epub March 23, 2018, PMID: 2957311.
Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97(12):3068–75.
Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli SF, Bertoni F, Guerra A, Capanna A, Albasinni U. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer. 1985; 56: 1515–1521.
Harrison DJ, Schwartz, MD. Osteogenic sarcoma: systemic chemotherapy options for localized disease. Curr Treat Options Oncol. 2017;18:24.
Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol. 1989;16(4):312–22.
Unni KK, Dahlin DC, Beabout JW, Ivins JC. Paraosteal osteogenic sarcoma. Cancer. 1976;37:2466–75.
Claude L, Rousmans S, Bataillard A, Philip T. Fédération nationale des centres de lutte contre le cancer (FNCLCC); Fédération hospitalière de France (FHF); Fédération nationale de cancérologie des CHRU (FNCCHRU); Fédération française de cancérologie des CHG (FFCCHG); centres régionaux de lutte contre le cancer (CRLCC); Société française de lutte contre les cancers de l’enfant et de l’adolescent (SFCE). Standards and Options for the use of radiation therapy in the management of patients with osteosarcoma: Update 2004. Cancer Radiother. 2005; 9(2): 104–121. Review. French. PMID:1588088.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer-Verlag London Ltd., part of Springer Nature
About this chapter
Cite this chapter
Poitout, D.G. (2021). Osteosarcoma. In: Paulos, J., Poitout, D.G. (eds) Bone Tumors. Springer, London. https://doi.org/10.1007/978-1-4471-7501-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-4471-7501-8_5
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-7499-8
Online ISBN: 978-1-4471-7501-8
eBook Packages: MedicineMedicine (R0)